Provigil: A Case Study of Anticompetitive Behavior
Michael A. Carrier
Rutgers University School of Law - Camden
Hastings Science & Technology Law Journal, Vol. 3, No. 2, pp. 441-452, Summer 2011
Using the sleep-disorder drug Provigil as a case study, this short symposium piece explores the anticompetitive harm presented by the combination of two distinct activities.
First, brand-name drug firms such as Cephalon, the developer of Provigil, have settled patent litigation by paying generic firms to delay entering the market. Second, brand firms, frequently at the end of a patent term, have engaged in "product hopping," switching from one means of administering a drug (e.g., tablet) to another (e.g., capsule).
The story of Provigil demonstrates the harm that can result from the combination of these two activities.
Number of Pages in PDF File: 12
Keywords: patent, antitrust, settlements, product hopping, drugs, Hatch Waxman, Provigil, Cephalon
JEL Classification: I18, K21, L40, L41, L43, L65, O34, O38Accepted Paper Series
Date posted: October 15, 2011
© 2014 Social Science Electronic Publishing, Inc. All Rights Reserved.
This page was processed by apollo7 in 0.328 seconds